Efficacy in the first-line setting

LOQTORZI® + chemo extended PFS and OS in patients with R/M NPC longer than chemo alone1,2,4-6*

JUPITER-02: Progression-free Survival

Superior progression-free survival with LOQTORZI + chemo1,2*

BIRC-assessed median progression-free survival (primary end point per RECIST 1.1)1
  • Interim analysis†: 11.7 months with LOQTORZI + chemo (95% CI, 11.0-NE) vs 8 months with chemo alone (95% CI, 7.0-9.5); HR=0.52 (95% CI, 0.36-0.74)‡; P=0.0003§

Final analysis2§:

Progression-free survival of LOQTORZI® (toripalimab-tpzi) + chemo vs Placebo + chemo
  • Median PFS was 21.4 months with LOQTORZI + chemo (95% CI, 11.7-NE) vs 8.2 months with chemo alone (95% CI, 7.0-9.8)2
  • Number of PFS events: 63/146 (43%) with LOQTORZI + chemo and 87/143 (61%) with placebo + chemo3
Number of patients at risk by month, JUPITER-02 progression-free survival
Treatment arm 0 months6 months12 months18 months24 months30 months
LOQTORZI + chemo 146101644690
Placebo + chemo 14391311420

Rotate your device for the best viewing experience.

JUPITER-02: Progression-free Survival

Progression-free survival of LOQTORZI® (toripalimab-tpzi) + chemo vs Placebo + chemo
  • *Patients were treated with LOQTORZI + cisplatin and gemcitabine or placebo + cisplatin and gemcitabine for up to 6 cycles, followed by LOQTORZI alone or placebo alone.1
  • †Cutoff date for interim analysis was May 30, 2020.1
  • ‡Based on the stratified Cox proportional-hazards model using the stratification factors at randomization, ECOG performance status, and disease stage.1
  • §Two-sided P value, based on the stratified log-rank test, as compared with an alpha boundary of 0.010.1
  • Cutoff date for final analysis was June 8, 2021.2

JUPITER-02: Overall Survival

Significant reduction in the risk of death with LOQTORZI + chemo1,4*

More than half of all patients taking LOQTORZI + chemo remained alive at the time of final analysis† (secondary end point)

Overall survival

Not reached with LOQTORZI + chemo (95% CI, 38.7-NE)

vs

33.7 months with chemo alone (95% CI, 27.0-44.2)

37%

reduction in risk
of death

HR=0.63 (95% CI, 0.45-0.89); P=0.0083‡

Number of events was 57/146 (39%) with LOQTORZI + chemo vs 76/143 (53%) with chemo alone

  • *Patients were treated with LOQTORZI + cisplatin and gemcitabine or placebo + cisplatin and gemcitabine for up to 6 cycles, followed by LOQTORZI alone or placebo alone.1
  • †Cutoff date for final analysis was November 18, 2022; median follow-up was 36 months.1
  • ‡Two-sided P value, based on the stratified log-rank test, as compared with an alpha boundary of 0.049995.1

6-year overall survival follow-up data (post hoc analysis)5§

For best viewing, please rotate screen horizontally and expand chart

Overall survival of LOQTORZI® (toripalimab-tpzi) + chemo vs Placebo + chemo
  • Median follow-up was 36.8 months (range: 0.2-79.6 months)
  • Observed reduction in risk of death was 38% with LOQTORZI + chemo
This post hoc analysis was exploratory in nature and occurred after the protocol-specified final analysis.
Number of patients at risk by month, JUPITER-02 6-year overall survival follow-up
Treatment arm 0 months6 months12 months18 months24 months30 months36 months42 months48 months54 months60 months66 months72 months78 months84 months
LOQTORZI + chemo 146139129117107988564605247331220
Placebo + chemo 1431351211028673655141332817820

Rotate your device for the best viewing experience.

6-year overall survival follow-up data

Overall survival of LOQTORZI® (toripalimab-tpzi) + chemo vs Placebo + chemo
  • §After the prespecified final OS analysis was conducted, surviving patients were re-consented for long-term survival follow-up. Cutoff date for this follow-up analysis was June 24, 2025, 68 months after the last patient was enrolled.6

JUPITER-02: Overall Response Rate

Significantly more patients achieved a response with LOQTORZI + chemo1,2*

BIRC-assessed response rates (secondary end point)1:
  • Interim analysis: 77% overall response rate (95% CI, 70%-84%) with LOQTORZI + chemo (n=146) vs 66% (95% CI, 58%-74%) with chemo alone (n=143); P=0.0353†
    • 19% complete response rate with LOQTORZI + chemo (vs 11% with chemo alone)‡
    • 58% partial response rate with LOQTORZI + chemo (vs 55% with chemo alone)‡

Final analysis2§||:

Overall response rate of LOQTORZI® (toripalimab-tpzi) + chemo and Overall response rate of Placebo + chemo
  • *Patients were treated with LOQTORZI + cisplatin and gemcitabine or placebo + cisplatin and gemcitabine for up to 6 cycles, followed by LOQTORZI alone or placebo alone.1
  • †ORR results are based on the prespecified interim analysis with data cutoff of May 30, 2020.1
  • ‡Two-sided P value based upon Cochran-Mantel-Haenszel test.1
  • §BIRC assessed per RECIST v1.12
  • ||Cutoff date for final analysis was June 8, 2021.2
  • Computed using the Clopper-Pearson method.2
  • #Computed using the Cochran-Mantel-Haenszel method, stratified by the baseline ECOG performance status (0 vs 1) and the baseline disease stage (recurrent vs primary metastatic).2

JUPITER-02: Duration of Response

Duration of response was longer with LOQTORZI + chemo1,2*

BIRC-assessed duration of response (secondary end point)1:
  • Interim analysis: duration of response was 10 months with LOQTORZI + chemo (n=146; 95% CI, 8.8-NE) vs 5.7 months with chemo alone (n=143; 95% CI, 5.4-6.8)

Final analysis (secondary end point)2†:

Rotate your device for the best viewing experience.

JUPITER-02: Duration of Response

Duration of response of LOQTORZI® (toripalimab-tpzi) + chemo vs Placebo + chemo. Bar chart of BIRC-assessed duration of response, final analysis in JUPITER-02. 18 months with LOQTORZI + chemo (95% CI, 10.5-NE), n=115, versus 6 months with placebo + chemo (95% CI, 5.6-8.3), n=96.
  • *Patients were treated with LOQTORZI + cisplatin and gemcitabine or placebo + cisplatin and gemcitabine for up to 6 cycles, followed by LOQTORZI alone or placebo alone.1
  • †Cutoff date for final analysis was June 8, 2021.2
  • ‡CI for median survival computed using the Brookmeyer-Crowley method with log-log transformation.2

JUPITER-02: Trial Design

JUPITER-021,2

The efficacy of LOQTORZI in combination with cisplatin and gemcitabine was investigated in JUPITER-02, a randomized, multicenter, single-region,* double-blind, placebo-controlled trial in 289 adult patients with metastatic or recurrent locally advanced NPC who had not received previous systemic chemotherapy for recurrent or metastatic disease.†

JUPITER-02 trial design

289 patients were randomized 1:1 into two arms.

  • For up to 6 cycles: LOQTORZI 240 mg IV Q3W plus cisplatin and gemcitabine (n=146), then continued for up to 2 years on LOQTORZI 240 mg IV Q3W.
  • For up to 6 cycles: placebo IV Q3W plus cisplatin and gemcitabine (n=143), then continued for up to 2 years on placebo IV Q3W.

Treatment with LOQTORZI or placebo continued until disease progression per RECIST v1.1, unacceptable toxicity, or a maximum of 2 years. The primary end point was BIRC-assessed PFS per RECIST v1.1 criteria. The secondary end points were BIRC-assessed ORR, BIRC-assessed DOR, and OS.

Key eligibility and exclusion criteria1,2

Key eligibility criteria included primary metastatic or recurrent locally advanced NPC after curative-intent therapy, treatment naïve for R/M NPC, ECOG-PS 0-1, 18-75 years of age, and measurable disease per RECIST v1.1.

Key exclusion criteria included a history of severe hypersensitivity reactions to any monoclonal antibody, cisplatin or gemcitabine, or any ingredient of toripalimab; active or untreated central nervous system metastases; previous monoclonal antibody treatment targeting PD-1/PD-L1/CTLA-4; a history of bone marrow or solid organ transplantation; or a history of protocol-specified autoimmune disease.

Key demographics1

  • Median age was 48 years (range: 19 to 72); 4.8% were ≥65 years
  • 83% male
  • 100% Asian
  • 57% ECOG-PS 0
  • 86% had metastatic disease
Histological subtypes:
  • 98% nonkeratinizing
  • 1% keratinizing squamous cell carcinoma
  • 1% not identified
Previous therapy:
  • Approximately 59% received ≥1 prior systemic therapy for locally advanced disease, and 60% received prior radiation therapy
  • *The JUPITER-02 trial was conducted across 35 sites in mainland China, Taiwan, and Singapore.2
  • †Patients with recurrent NPC after treatment with curative intent were required to have an interval of at least 6 months between the last dose of radiotherapy or chemotherapy and recurrence. Patients with autoimmune disease, other than stable hypothyroidism or type 1 diabetes, and patients who required systemic immunosuppression were ineligible.1
Dr. Victoria Villaflor

Hear an expert’s perspective

Watch Dr. Victoria Villaflor discuss the JUPITER-02 trial comparing LOQTORZI + chemo vs chemo alone, including the 6-year overall survival follow-up data.

Rotate your device for the best viewing experience.

JUPITER-02 expert perspective

Dr. Victoria Villaflor discusses the JUPITER-02 trial comparing LOQTORZI + chemo vs chemo alone, including the 6-year overall survival follow-up, in patients with metastatic or recurrent locally advanced nasopharyngeal carcinoma.

JUPITER-02 Safety

See the safety data from the JUPITER-02 trial.

Learn more

POLARIS-02 Efficacy

See LOQTORZI results as a monotherapy in the subsequent-line setting.

Learn more

BIRC=blinded independent review committee; CI=confidence interval; CTLA-4=cytotoxic T-lymphocyte–associated protein 4; ECOG=Eastern Cooperative Oncology Group; HR=hazard ratio; mPFS=median progression-free survival; NE=not estimable; ORR=objective response rate; OS=overall survival; PD-L1=programmed death-ligand 1; PFS=progression-free survival;

References:

  1. LOQTORZI® (toripalimab-tpzi) Prescribing Information. Redwood City, CA: Coherus Oncology, Inc.
  2. Mai H-Q, Chen Q-Y, Chen D, et al. Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial. JAMA. 2023;330(20):1961-1970. doi:10.1001/jama.2023.20181
  3. Mai H-Q, Chen Q-Y, Chen D, et al. Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. Abstract presented at: American Association for Cancer Research Annual Meeting 2022; April 8-13, 2022; New Orleans, LA.
  4. Data on file. Coherus Oncology, Inc.
  5. Chen Q-Y. Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. Mini oral session presented at: ESMO Asia Congress; December 5-7, 2025; Singapore.
  6. Mai H-Q, Chen Q-Y, Chen D, et al. Final overall survival analysis of JUPITER-02: a phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. Abstract presented at: ESMO Asia Congress; December 5-7, 2025; Singapore. Accessed December 2, 2025. https://cpaper.ctimeetingtech.com/asia2025/submission/preview/print?publication_id=1279.

Important Safety Information and Indications

See Indications

Important Safety Information

Severe and Fatal Immune-Mediated Adverse Reactions

Immune-mediated adverse reactions listed herein may not include all possible severe and fatal immune-mediated adverse reactions. Immune-mediated adverse reactions, which can be severe or fatal, occur in any organ system or tissue, affect more than one body system simultaneously, and occur at any time after starting PD-1/PD-L1 blocking antibody. While immune-mediated adverse reactions usually manifest during treatment, they can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies.

INDICATIONS

LOQTORZI® (toripalimab-tpzi) is indicated:

  • In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).
  • As a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.

Severe and Fatal Immune-Mediated Adverse Reactions (cont’d)

  • Monitor for early identification and management. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.
  • Withhold or permanently discontinue LOQTORZI based on severity and type of reaction (see Dosage and Administration in Prescribing Information). In general, if LOQTORZI requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.

Immune-Mediated Pneumonitis

LOQTORZI can cause immune-mediated pneumonitis.

  • In patients receiving LOQTORZI in combination with cisplatin and gemcitabine, immune-mediated pneumonitis occurred in 2.1% (3/146) of patients, including Grade 2 (1.4%) adverse reactions. Pneumonitis resolved in 67% (2/3) of these patients.
  • In patients receiving LOQTORZI monotherapy, immune-mediated pneumonitis occurred in 2.6% (22/851) of patients, including fatal (0.2%), Grade 3 (0.7%), and Grade 2 (1.1%) adverse reactions. Systemic corticosteroids were required in 82% (18/22) of patients with pneumonitis. Pneumonitis led to permanent discontinuation of LOQTORZI in 1.2% (10/851) of patients. Pneumonitis resolved in 23% (5/22) of these patients.

Immune-Mediated Colitis

LOQTORZI can cause immune-mediated colitis, which may present with diarrhea. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies. In patients receiving LOQTORZI monotherapy, immune-mediated colitis occurred in 0.4% (3/851) of patients, including Grade 3 (0.2%) and Grade 2 (0.1%) adverse reactions. Colitis resolved in all 3 patients.

Hepatotoxicity and Immune-Mediated Hepatitis

LOQTORZI can cause immune-mediated hepatitis.

  • In patients receiving LOQTORZI in combination with cisplatin and gemcitabine, immune-mediated hepatitis occurred in 0.7% (1/146) of patients, which was a Grade 3 (0.7%) adverse reaction. The patient with immune-mediated hepatitis required systemic corticosteroids.
  • In patients receiving LOQTORZI monotherapy, immune-mediated hepatitis occurred in 3.3% (28/851) of patients, including Grade 4 (0.8%), Grade 3 (2.1%), and Grade 2 (0.4%) adverse reactions. Hepatitis led to permanent discontinuation of LOQTORZI in 1.1% of patients and withholding of LOQTORZI in 0.8% of patients. Hepatitis resolved in 54% (15/28) of these patients.

Immune-Mediated Endocrinopathies

Adrenal Insufficiency

LOQTORZI can cause primary or secondary adrenal insufficiency. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold or permanently discontinue LOQTORZI depending on severity. In patients receiving LOQTORZI monotherapy, adrenal insufficiency occurred in 0.5% (4/851) of patients, including Grade 2 (0.4%) and Grade 1 (0.1%) adverse reactions. Systemic corticosteroids were required in 75% (3/4) of the patients with adrenal insufficiency. Adrenal insufficiency led to withholding of LOQTORZI in 0.1% (1/851) of patients. In the one patient in whom LOQTORZI was withheld, LOQTORZI was reinitiated after symptom improvement.

Hypophysitis

LOQTORZI can cause immune-mediated hypophysitis. Hypophysitis can present with acute symptoms associated with mass effects such as headache, photophobia, or visual field defects. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as indicated. Withhold or permanently discontinue LOQTORZI depending on severity. In patients receiving LOQTORZI monotherapy, hypophysitis occurred in 0.4% (3/851) of patients receiving LOQTORZI, including Grade 3 (0.2%) and Grade 2 (0.1%) adverse reactions. All three patients received systemic corticosteroids. Hypophysitis led to permanent discontinuation of LOQTORZI in 0.1% (1/851) of patients and withholding of LOQTORZI in 0.1% (1/851) of patients. The one patient in whom LOQTORZI was withheld reinitiated LOQTORZI.

Thyroid Disorders

LOQTORZI can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or institute medical management of hyperthyroidism as clinically indicated. Withhold or permanently discontinue LOQTORZI depending on severity.

  • In patients receiving LOQTORZI in combination with cisplatin and gemcitabine, thyroiditis occurred in 2.1% (3/146) of patients receiving LOQTORZI, including Grade 2 (1.4%). Three patients required thyroid hormone replacement therapy. Thyroiditis resolved in one of the 3 patients. Hyperthyroidism occurred in 1.4% (2/146) of patients receiving LOQTORZI in combination with cisplatin and gemcitabine. Hyperthyroidism resolved in these 2 patients. Hypothyroidism occurred in 30% (44/146) of patients receiving LOQTORZI in combination with cisplatin and gemcitabine, including Grade 2 (24%) and Grade 1 (6%). Eighty percent of the 44 patients required thyroid hormone replacement therapy. LOQTORZI was withheld in 2.1% (3/146) of the patients. Of the 3 patients in whom LOQTORZI was withheld, 2 patients reinitiated LOQTORZI.
  • In patients receiving LOQTORZI monotherapy, thyroiditis occurred in 0.6% (5/851) patients receiving LOQTORZI, including Grade 2 (0.1%). Two of these 5 patients received systemic corticosteroids and 2 required thyroid hormone replacement therapy. Thyroiditis resolved in 2 of the 5 patients. Hyperthyroidism occurred in 7% (55/851) of patients receiving LOQTORZI, including Grade 2 (1.9%). Hyperthyroidism resolved in 85% (47/55) of the patients. Hypothyroidism occurred in 15% (128/851) of patients receiving LOQTORZI, including Grade 2 (8%). Sixty three percent of the 128 patients required thyroid hormone replacement therapy. LOQTORZI was withheld in 0.5% of patients. Of the 4 patients in whom LOQTORZI was withheld, 3 patients reinitiated LOQTORZI.
Type 1 Diabetes Mellitus, which can present with Diabetic Ketoacidosis

Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold or permanently discontinue LOQTORZI depending on severity. In patients receiving LOQTORZI monotherapy, diabetes mellitus occurred in 0.9% (8/851) of patients receiving LOQTORZI, including Grade 4 (0.1%), Grade 3 (0.7%), and Grade 2 (0.1%). Diabetes mellitus led to permanent discontinuation in 0.4% of patients. Six of the 8 (75%) patients with diabetes mellitus required long-term insulin therapy.

Immune-Mediated Nephritis with Renal Dysfunction

LOQTORZI can cause immune-mediated nephritis.

  • In patients receiving LOQTORZI in combination with cisplatin and gemcitabine, immune-mediated nephritis occurred in 0.7% (1/146) of patients receiving LOQTORZI. The one patient with immune-mediated nephritis (Grade 4) required systemic corticosteroids and nephritis led to discontinuation of LOQTORZI. Nephritis resolved in this patient.
  • In patients receiving LOQTORZI monotherapy, immune-mediated nephritis occurred in 0.5% (4/851) of patients, including Grade 3 (0.5%) adverse reactions. Nephritis resolved in 75% (3/4) of these patients.

Immune-Mediated Dermatologic Adverse Reactions

LOQTORZI can cause immune-mediated rash or dermatitis. Exfoliative dermatitis, including Stevens-Johnson Syndrome (SJS), drug rash with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis (TEN), has occurred with PD-1/PD-L1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes. Withhold or permanently discontinue LOQTORZI depending on severity.

  • In patients receiving LOQTORZI in combination with cisplatin and gemcitabine, immune-mediated dermatologic adverse reactions occurred in 8% (12/146) of patients, including Grade 3 (3.4%) and Grade 2 (1.4%) adverse reactions. Systemic corticosteroids were required in 25% (3/12) of the patients with immune-mediated dermatologic adverse reactions. Immune-mediated dermatologic adverse reactions led to permanent discontinuation of LOQTORZI in 2.1% (3) of patients. Immune-mediated dermatologic adverse reactions resolved in 92% (11/12) of these patients.
  • In patients receiving LOQTORZI monotherapy, immune-mediated dermatologic adverse reactions occurred in 4% (34/851) of patients, including Grade 3 (0.4%) and Grade 2 (1.4%) adverse reactions. Immune-mediated dermatologic adverse reactions led to withholding of LOQTORZI in 0.4% (3) of the patients. Systemic corticosteroids were required in 12% (4/34) of the patients with immune-mediated dermatologic adverse reactions. Immune-mediated dermatologic adverse reactions resolved in 71% (24/34) of these patients.

Other Immune-Mediated Adverse Reactions

The following clinically significant immune-mediated adverse reactions occurred at an incidence of <1% (unless otherwise noted) in patients who received LOQTORZI or were reported with the use of other PD-1/PD-L1 blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions.

  • Cardiac/Vascular: Myocarditis, pericarditis, vasculitis, pericardial effusion
  • Nervous System: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy
  • Ocular: Uveitis, iritis and other ocular inflammatory toxicities can occur. Some cases can be associated with retinal detachment. Various grades of visual impairment, including blindness, can occur. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss.
  • Gastrointestinal: Pancreatitis, to include increases in serum amylase and lipase levels, gastritis, duodenitis
  • Musculoskeletal and Connective Tissue: Myositis/polymyositis, rhabdomyolysis (and associated sequelae, including renal failure), arthritis, polymyalgia rheumatica, dermatomyositis
  • Endocrine: Hypoparathyroidism
  • Hematologic/Immune: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection
  • Other: Myocarditis-Myositis-Myasthenia Gravis (or Myasthenia-Like) Overlap Syndrome, reported as the co-occurrence of either two or all three adverse reactions

Infusion-Related Reactions

LOQTORZI can cause severe or life-threatening infusion-related reactions including hypersensitivity and anaphylaxis.

  • In patients receiving LOQTORZI in combination with cisplatin and gemcitabine, infusion-related reactions have been reported in 4.1% of patients, including Grade 2 (0.7%) reactions.
  • In patients receiving LOQTORZI monotherapy, infusion-related reactions occurred in 2% of 851 patients, including Grade 3 (0.1%) and Grade 2 (0.6%). LOQTORZI was withheld for one Grade 3 infusion related reaction. Monitor patients for signs and symptoms of infusion-related reactions including rigors, chills, wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever. Interrupt or slow the rate of infusion for mild (Grade 1) or moderate (Grade 2) infusion-related reactions. For severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions, stop infusion and permanently discontinue LOQTORZI.

Complications of Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1 blocking antibody. Transplant-related complications include hyperacute graft-versus-host-disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease (VOD) after reduced intensity conditioning, and steroid requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockade and allogeneic HSCT. Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefit versus risks of treatment with a PD-1/PD-L1 blocking antibody prior to or after an allogeneic HSCT.

Embryo-Fetal Toxicity

LOQTORZI can cause fetal harm when administered to a pregnant woman. Animal studies have demonstrated that inhibition of the PD-1/PD-L1 pathway can lead to increased risk of immune-mediated rejection of the developing fetus resulting in fetal death. Advise women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with LOQTORZI and for 4 months after the last dose.

Lactation

There are no data on the presence of toripalimab-tpzi in human milk; its effects on the breastfed child, or on milk production. Maternal IgG is known to be present in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed child to toripalimab-tpzi are unknown. Because of the potential for serious adverse reactions in breastfed children, advise lactating women not to breastfeed during treatment with LOQTORZI and for 4 months after the last dose.

Serious Adverse Reactions

  • In JUPITER-02, when LOQTORZI was administered in combination with cisplatin and gemcitabine for the first-line treatment of recurrent, locally advanced or metastatic nasopharyngeal carcinoma, serious adverse reactions occurred in 43% of patients. Serious adverse drug reactions in ≥2% were thrombocytopenia (14%), neutrophil count decreased (10%), pneumonia (10%), anemia (9%), abnormal hepatic function (2.7%), and rash (2.1%). There were three fatal adverse reactions (2.1%): one due to epistaxis; one due to intracranial hemorrhage associated with immune-related thrombocytopenia and coagulopathy; and one due to pneumonia. Permanent discontinuation of LOQTORZI, due to an adverse reaction occurred in 12% of patients. Adverse reactions resulting in permanent discontinuation of LOQTORZI in ≥1% were pneumonia (2.1%), pulmonary tuberculosis (1.4%), rash (1.4%), and vomiting (1.4%). The most common Grade 3 to 4 laboratory abnormalities (≥2%) were decreased neutrophils (58%), decreased lymphocytes (57%), decreased hemoglobin (50%), decreased platelets (33%), decreased potassium (10%), decreased sodium (9%), increased alanine aminotransferase (6%), increased or decreased magnesium (4.2% each), decreased calcium (3.5%), increased aspartate aminotransferase (2.7%), and increased bilirubin (2.1%).
  • In POLARIS-02, when LOQTORZI was administered as a single agent to patients with previously treated, unresectable or metastatic nasopharyngeal carcinoma, serious adverse reactions occurred in 24% of patients. Serious adverse drug reactions in ≥2% were pneumonia (4.7%), abnormal hepatic function (2.6%), and hyperbilirubinemia (2.1%). Fatal adverse reactions occurred in 3.7% of patients who received LOQTORZI, including death not otherwise specified (1.6%), tumor hemorrhage (0.5%), hepatic failure and thrombocytopenia (0.5%), hyponatremia (0.5%), and sudden death (0.5%). Permanent discontinuation of LOQTORZI due to an adverse reaction occurred in 9% of patients. Adverse reactions resulting in permanent discontinuation of LOQTORZI in ≥1% included pneumonia (1.1%), abnormal hepatic function (1.1%), and hyperbilirubinemia (1.1%). The most common Grade 3 or 4 laboratory abnormalities (≥2%), were decreased sodium (11%), decreased lymphocytes (9%), decreased hemoglobin (6%), increased aspartate aminotransferase (3.8%), decreased phosphate (3.2%), and increased alkaline phosphatase (2.2%).

Common Adverse Reactions

  • In JUPITER-02, the most common adverse reactions (≥20%) were nausea (71%), vomiting (68%), decreased appetite (55%), constipation (39%), hypothyroidism (38%), rash (36%), pyrexia (32%), diarrhea (31%), peripheral neuropathy (30%), cough (26%), musculoskeletal pain (25%), upper respiratory infection (23%), insomnia (23%), dizziness (21%), and malaise (21%).
  • In POLARIS-02, in patients with previously treated, unresectable or metastatic nasopharyngeal carcinoma, the most common (≥20%) adverse reactions were hypothyroidism (27%), fatigue (22%), and cough (20%).

LOQTORZI® Injection: 240 mg/6 mL (40 mg/mL) solution in a single-dose vial

Please see Prescribing Information for LOQTORZI.

Are you a US healthcare
professional?

This information is intended for US healthcare professionals.

No, I am not